Immune responses to recombinant Brugia malayi pepsin inhibitor homolog (Bm-33) in patients with human lymphatic filariaisis.
Identifieur interne : 002876 ( PubMed/Curation ); précédent : 002875; suivant : 002877Immune responses to recombinant Brugia malayi pepsin inhibitor homolog (Bm-33) in patients with human lymphatic filariaisis.
Auteurs : N S A. Krushna [Inde] ; C. Shiny ; G. Manokaran ; S. Elango ; S. Babu ; R B NarayananSource :
- Parasitology research [ 1432-1955 ] ; 2011.
Descripteurs français
- KwdFr :
- ADN complémentaire (biosynthèse), ADN complémentaire (génétique), ADN complémentaire (métabolisme), Activation des lymphocytes (), Activation des lymphocytes (immunologie), Agranulocytes (), Agranulocytes (immunologie), Animaux, Anticorps antihelminthe (sang), Antigènes d'helminthe (immunologie), Antigènes d'helminthe (usage thérapeutique), Brugia malayi (immunologie), Cellules cultivées, Cytokines (génétique), Cytokines (métabolisme), Facteurs immunologiques (immunologie), Facteurs immunologiques (usage thérapeutique), Filariose lymphatique (immunologie), Filariose lymphatique (sang), Filariose lymphatique (traitement médicamenteux), Humains, Immunité cellulaire (), Immunité cellulaire (immunologie), Lymphocytes T (), Lymphocytes T (immunologie), Prolifération cellulaire (), Protéines d'helminthes (immunologie), Protéines d'helminthes (usage thérapeutique), Protéines recombinantes (immunologie), RT-PCR, Régulation de l'expression des gènes ().
- MESH :
- biosynthèse : ADN complémentaire.
- génétique : ADN complémentaire, Cytokines.
- immunologie : Activation des lymphocytes, Agranulocytes, Antigènes d'helminthe, Brugia malayi, Facteurs immunologiques, Filariose lymphatique, Immunité cellulaire, Lymphocytes T, Protéines d'helminthes, Protéines recombinantes.
- métabolisme : ADN complémentaire, Cytokines.
- sang : Anticorps antihelminthe, Filariose lymphatique.
- traitement médicamenteux : Filariose lymphatique.
- usage thérapeutique : Antigènes d'helminthe, Facteurs immunologiques, Protéines d'helminthes.
- Activation des lymphocytes, Agranulocytes, Animaux, Cellules cultivées, Humains, Immunité cellulaire, Lymphocytes T, Prolifération cellulaire, RT-PCR, Régulation de l'expression des gènes.
English descriptors
- KwdEn :
- Animals, Antibodies, Helminth (blood), Antigens, Helminth (immunology), Antigens, Helminth (therapeutic use), Brugia malayi (immunology), Cell Proliferation (drug effects), Cells, Cultured, Cytokines (genetics), Cytokines (metabolism), DNA, Complementary (biosynthesis), DNA, Complementary (genetics), DNA, Complementary (metabolism), Elephantiasis, Filarial (blood), Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (immunology), Gene Expression Regulation (drug effects), Helminth Proteins (immunology), Helminth Proteins (therapeutic use), Humans, Immunity, Cellular (drug effects), Immunity, Cellular (immunology), Immunologic Factors (immunology), Immunologic Factors (therapeutic use), Leukocytes, Mononuclear (drug effects), Leukocytes, Mononuclear (immunology), Lymphocyte Activation (drug effects), Lymphocyte Activation (immunology), Recombinant Proteins (immunology), Reverse Transcriptase Polymerase Chain Reaction, T-Lymphocytes (drug effects), T-Lymphocytes (immunology).
- MESH :
- chemical , biosynthesis : DNA, Complementary.
- chemical , blood : Antibodies, Helminth.
- chemical , genetics : Cytokines, DNA, Complementary.
- chemical , immunology : Antigens, Helminth, Helminth Proteins, Immunologic Factors, Recombinant Proteins.
- chemical , metabolism : Cytokines, DNA, Complementary.
- chemical , therapeutic use : Antigens, Helminth, Helminth Proteins, Immunologic Factors.
- blood : Elephantiasis, Filarial.
- drug effects : Cell Proliferation, Gene Expression Regulation, Immunity, Cellular, Leukocytes, Mononuclear, Lymphocyte Activation, T-Lymphocytes.
- drug therapy : Elephantiasis, Filarial.
- immunology : Brugia malayi, Elephantiasis, Filarial, Immunity, Cellular, Leukocytes, Mononuclear, Lymphocyte Activation, T-Lymphocytes.
- Animals, Cells, Cultured, Humans, Reverse Transcriptase Polymerase Chain Reaction.
Abstract
Immune responses to recombinant Brugia malayi pepsin inhibitor homolog (rBm-33) were investigated in patients with human lymphatic filariasis (microfilaremics (MF) and chronic pathology (CP)) along with endemic normals (EN). Flow cytometric analysis (24 h) revealed CD4(+) T cell activation in patients (MF and CP) compared to normals (EN), with increased expression of CD69 and diminished levels of CD62L and CD127. This was associated with an elevated expression of CD154 but not CD28 and CTLA4 in CP patients. However, Bm-33-induced cytokine expression profile (IL-1β, IL-12, IL-8, IFN-γ, IL-10 and TGF-β) did not exhibit any significant difference between normals and patients at the same time point. Although CD4(+) T cell activation was observed initially in filarial patients (24 h), lymphoproliferation studies (96 h) suggested diminished proliferation compared to normals, indicating functional inactivation in the former upon prolonged antigen exposure. This indicates that rBm-33 induces an early T cell activation in MF and CP patients followed by a decreased lymphoproliferation that might contribute to immune suppression in these individuals.
DOI: 10.1007/s00436-010-2081-x
PubMed: 20927633
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002876
Links to Exploration step
pubmed:20927633Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immune responses to recombinant Brugia malayi pepsin inhibitor homolog (Bm-33) in patients with human lymphatic filariaisis.</title><author><name sortKey="Krushna, N S A" sort="Krushna, N S A" uniqKey="Krushna N" first="N S A" last="Krushna">N S A. Krushna</name><affiliation wicri:level="1"><nlm:affiliation>Centre for Biotechnology, Anna University, Guindy, Chennai, 600025, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Centre for Biotechnology, Anna University, Guindy, Chennai, 600025</wicri:regionArea></affiliation></author><author><name sortKey="Shiny, C" sort="Shiny, C" uniqKey="Shiny C" first="C" last="Shiny">C. Shiny</name></author><author><name sortKey="Manokaran, G" sort="Manokaran, G" uniqKey="Manokaran G" first="G" last="Manokaran">G. Manokaran</name></author><author><name sortKey="Elango, S" sort="Elango, S" uniqKey="Elango S" first="S" last="Elango">S. Elango</name></author><author><name sortKey="Babu, S" sort="Babu, S" uniqKey="Babu S" first="S" last="Babu">S. Babu</name></author><author><name sortKey="Narayanan, R B" sort="Narayanan, R B" uniqKey="Narayanan R" first="R B" last="Narayanan">R B Narayanan</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:20927633</idno><idno type="pmid">20927633</idno><idno type="doi">10.1007/s00436-010-2081-x</idno><idno type="wicri:Area/PubMed/Corpus">002876</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002876</idno><idno type="wicri:Area/PubMed/Curation">002876</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002876</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Immune responses to recombinant Brugia malayi pepsin inhibitor homolog (Bm-33) in patients with human lymphatic filariaisis.</title><author><name sortKey="Krushna, N S A" sort="Krushna, N S A" uniqKey="Krushna N" first="N S A" last="Krushna">N S A. Krushna</name><affiliation wicri:level="1"><nlm:affiliation>Centre for Biotechnology, Anna University, Guindy, Chennai, 600025, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Centre for Biotechnology, Anna University, Guindy, Chennai, 600025</wicri:regionArea></affiliation></author><author><name sortKey="Shiny, C" sort="Shiny, C" uniqKey="Shiny C" first="C" last="Shiny">C. Shiny</name></author><author><name sortKey="Manokaran, G" sort="Manokaran, G" uniqKey="Manokaran G" first="G" last="Manokaran">G. Manokaran</name></author><author><name sortKey="Elango, S" sort="Elango, S" uniqKey="Elango S" first="S" last="Elango">S. Elango</name></author><author><name sortKey="Babu, S" sort="Babu, S" uniqKey="Babu S" first="S" last="Babu">S. Babu</name></author><author><name sortKey="Narayanan, R B" sort="Narayanan, R B" uniqKey="Narayanan R" first="R B" last="Narayanan">R B Narayanan</name></author></analytic><series><title level="j">Parasitology research</title><idno type="eISSN">1432-1955</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Helminth (blood)</term><term>Antigens, Helminth (immunology)</term><term>Antigens, Helminth (therapeutic use)</term><term>Brugia malayi (immunology)</term><term>Cell Proliferation (drug effects)</term><term>Cells, Cultured</term><term>Cytokines (genetics)</term><term>Cytokines (metabolism)</term><term>DNA, Complementary (biosynthesis)</term><term>DNA, Complementary (genetics)</term><term>DNA, Complementary (metabolism)</term><term>Elephantiasis, Filarial (blood)</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (immunology)</term><term>Gene Expression Regulation (drug effects)</term><term>Helminth Proteins (immunology)</term><term>Helminth Proteins (therapeutic use)</term><term>Humans</term><term>Immunity, Cellular (drug effects)</term><term>Immunity, Cellular (immunology)</term><term>Immunologic Factors (immunology)</term><term>Immunologic Factors (therapeutic use)</term><term>Leukocytes, Mononuclear (drug effects)</term><term>Leukocytes, Mononuclear (immunology)</term><term>Lymphocyte Activation (drug effects)</term><term>Lymphocyte Activation (immunology)</term><term>Recombinant Proteins (immunology)</term><term>Reverse Transcriptase Polymerase Chain Reaction</term><term>T-Lymphocytes (drug effects)</term><term>T-Lymphocytes (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ADN complémentaire (biosynthèse)</term><term>ADN complémentaire (génétique)</term><term>ADN complémentaire (métabolisme)</term><term>Activation des lymphocytes ()</term><term>Activation des lymphocytes (immunologie)</term><term>Agranulocytes ()</term><term>Agranulocytes (immunologie)</term><term>Animaux</term><term>Anticorps antihelminthe (sang)</term><term>Antigènes d'helminthe (immunologie)</term><term>Antigènes d'helminthe (usage thérapeutique)</term><term>Brugia malayi (immunologie)</term><term>Cellules cultivées</term><term>Cytokines (génétique)</term><term>Cytokines (métabolisme)</term><term>Facteurs immunologiques (immunologie)</term><term>Facteurs immunologiques (usage thérapeutique)</term><term>Filariose lymphatique (immunologie)</term><term>Filariose lymphatique (sang)</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Humains</term><term>Immunité cellulaire ()</term><term>Immunité cellulaire (immunologie)</term><term>Lymphocytes T ()</term><term>Lymphocytes T (immunologie)</term><term>Prolifération cellulaire ()</term><term>Protéines d'helminthes (immunologie)</term><term>Protéines d'helminthes (usage thérapeutique)</term><term>Protéines recombinantes (immunologie)</term><term>RT-PCR</term><term>Régulation de l'expression des gènes ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>DNA, Complementary</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Helminth</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Cytokines</term><term>DNA, Complementary</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antigens, Helminth</term><term>Helminth Proteins</term><term>Immunologic Factors</term><term>Recombinant Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Cytokines</term><term>DNA, Complementary</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antigens, Helminth</term><term>Helminth Proteins</term><term>Immunologic Factors</term></keywords><keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>ADN complémentaire</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cell Proliferation</term><term>Gene Expression Regulation</term><term>Immunity, Cellular</term><term>Leukocytes, Mononuclear</term><term>Lymphocyte Activation</term><term>T-Lymphocytes</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>ADN complémentaire</term><term>Cytokines</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Activation des lymphocytes</term><term>Agranulocytes</term><term>Antigènes d'helminthe</term><term>Brugia malayi</term><term>Facteurs immunologiques</term><term>Filariose lymphatique</term><term>Immunité cellulaire</term><term>Lymphocytes T</term><term>Protéines d'helminthes</term><term>Protéines recombinantes</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Brugia malayi</term><term>Elephantiasis, Filarial</term><term>Immunity, Cellular</term><term>Leukocytes, Mononuclear</term><term>Lymphocyte Activation</term><term>T-Lymphocytes</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>ADN complémentaire</term><term>Cytokines</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antihelminthe</term><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antigènes d'helminthe</term><term>Facteurs immunologiques</term><term>Protéines d'helminthes</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cells, Cultured</term><term>Humans</term><term>Reverse Transcriptase Polymerase Chain Reaction</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Activation des lymphocytes</term><term>Agranulocytes</term><term>Animaux</term><term>Cellules cultivées</term><term>Humains</term><term>Immunité cellulaire</term><term>Lymphocytes T</term><term>Prolifération cellulaire</term><term>RT-PCR</term><term>Régulation de l'expression des gènes</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Immune responses to recombinant Brugia malayi pepsin inhibitor homolog (rBm-33) were investigated in patients with human lymphatic filariasis (microfilaremics (MF) and chronic pathology (CP)) along with endemic normals (EN). Flow cytometric analysis (24 h) revealed CD4(+) T cell activation in patients (MF and CP) compared to normals (EN), with increased expression of CD69 and diminished levels of CD62L and CD127. This was associated with an elevated expression of CD154 but not CD28 and CTLA4 in CP patients. However, Bm-33-induced cytokine expression profile (IL-1β, IL-12, IL-8, IFN-γ, IL-10 and TGF-β) did not exhibit any significant difference between normals and patients at the same time point. Although CD4(+) T cell activation was observed initially in filarial patients (24 h), lymphoproliferation studies (96 h) suggested diminished proliferation compared to normals, indicating functional inactivation in the former upon prolonged antigen exposure. This indicates that rBm-33 induces an early T cell activation in MF and CP patients followed by a decreased lymphoproliferation that might contribute to immune suppression in these individuals.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20927633</PMID><DateCreated><Year>2011</Year><Month>01</Month><Day>21</Day></DateCreated><DateCompleted><Year>2011</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1955</ISSN><JournalIssue CitedMedium="Internet"><Volume>108</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Parasitology research</Title><ISOAbbreviation>Parasitol. Res.</ISOAbbreviation></Journal><ArticleTitle>Immune responses to recombinant Brugia malayi pepsin inhibitor homolog (Bm-33) in patients with human lymphatic filariaisis.</ArticleTitle><Pagination><MedlinePgn>407-15</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00436-010-2081-x</ELocationID><Abstract><AbstractText>Immune responses to recombinant Brugia malayi pepsin inhibitor homolog (rBm-33) were investigated in patients with human lymphatic filariasis (microfilaremics (MF) and chronic pathology (CP)) along with endemic normals (EN). Flow cytometric analysis (24 h) revealed CD4(+) T cell activation in patients (MF and CP) compared to normals (EN), with increased expression of CD69 and diminished levels of CD62L and CD127. This was associated with an elevated expression of CD154 but not CD28 and CTLA4 in CP patients. However, Bm-33-induced cytokine expression profile (IL-1β, IL-12, IL-8, IFN-γ, IL-10 and TGF-β) did not exhibit any significant difference between normals and patients at the same time point. Although CD4(+) T cell activation was observed initially in filarial patients (24 h), lymphoproliferation studies (96 h) suggested diminished proliferation compared to normals, indicating functional inactivation in the former upon prolonged antigen exposure. This indicates that rBm-33 induces an early T cell activation in MF and CP patients followed by a decreased lymphoproliferation that might contribute to immune suppression in these individuals.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Krushna</LastName><ForeName>N S A</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Centre for Biotechnology, Anna University, Guindy, Chennai, 600025, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shiny</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Manokaran</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Elango</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Babu</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Narayanan</LastName><ForeName>R B</ForeName><Initials>RB</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Z99 AI999999</GrantID><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Parasitol Res</MedlineTA><NlmUniqueID>8703571</NlmUniqueID><ISSNLinking>0932-0113</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000909">Antibodies, Helminth</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000947">Antigens, Helminth</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C540446">Bm-33 protein, Brugia malayi</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018076">DNA, Complementary</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015801">Helminth Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Immunol Today. 1997 Feb;18(2):72-6</RefSource><PMID Version="1">9057357</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 1998 Apr 10;280(5361):243-8</RefSource><PMID Version="1">9535647</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Biochem. 1998 May 1;253(3):804-9</RefSource><PMID Version="1">9654082</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Immunol Today. 1998 Jul;19(7):291-3</RefSource><PMID Version="1">9666598</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Microbiol Immunol. 1999;43(3):279-83</RefSource><PMID Version="1">10338198</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Immunol. 2005 Mar;26(3):172-6</RefSource><PMID Version="1">15745860</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Infect Immun. 2005 Jun;73(6):3385-93</RefSource><PMID Version="1">15908365</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2006 Mar 1;176(5):3248-56</RefSource><PMID Version="1">16493086</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Microbiol Immunol. 2009 Mar;53(3):173-83</RefSource><PMID Version="1">19302528</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2000 Nov 1;165(9):5161-9</RefSource><PMID Version="1">11046048</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parasite Immunol. 2001 Jul;23(7):327-44</RefSource><PMID Version="1">11472553</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Annu Rev Immunol. 2002;20:551-79</RefSource><PMID Version="1">11861612</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Immunol. 2002 Mar;32(3):858-67</RefSource><PMID Version="1">11870630</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Parasitol. 2003 Dec;19(12):565-70</RefSource><PMID Version="1">14642766</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Annu Rev Immunol. 2004;22:745-63</RefSource><PMID Version="1">15032595</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 1987 May;79(5):1516-23</RefSource><PMID Version="1">3553242</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 1993 Apr;167(4):925-31</RefSource><PMID Version="1">8450257</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Biochem Parasitol. 1993 Nov;62(1):143-6</RefSource><PMID Version="1">8114819</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 1994 Jul;170(1):247-50</RefSource><PMID Version="1">8014511</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Immunol. 1994 Dec;24(12):3148-54</RefSource><PMID Version="1">7528671</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Immunol. 1995 Apr;25(4):1125-8</RefSource><PMID Version="1">7537673</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 1996 Mar;173(3):769-73</RefSource><PMID Version="1">8627051</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000909" MajorTopicYN="N">Antibodies, Helminth</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000947" MajorTopicYN="N">Antigens, Helminth</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017178" MajorTopicYN="N">Brugia malayi</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018076" MajorTopicYN="N">DNA, Complementary</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015801" MajorTopicYN="N">Helminth Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">NIHMS423938</OtherID><OtherID Source="NLM">PMC3515686</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>06</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>09</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20927633</ArticleId><ArticleId IdType="doi">10.1007/s00436-010-2081-x</ArticleId><ArticleId IdType="pmc">PMC3515686</ArticleId><ArticleId IdType="mid">NIHMS423938</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002876 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002876 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:20927633
|texte= Immune responses to recombinant Brugia malayi pepsin inhibitor homolog (Bm-33) in patients with human lymphatic filariaisis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:20927633" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |